Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q ...
The deceleration in CKD prevalence growth after 2012, along with the declining incidence trends may reflect the impact of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback